Company news

Tarsus Pharmaceuticals, Inc. news in 2021

Tarsus Pharmaceuticals, Inc.'s news releases, calls and decks from 2021, newest first.

View company

Tarsus to Participate at Upcoming Virtual Investor Conferences

November 22, 2021

Tarsus to Participate in the Virtual Jefferies London Healthcare Conference 2021

November 9, 2021

Tarsus Pharmaceuticals, Inc. Reports Third Quarter 2021 Financial Results and Recent Business Achievements

November 8, 2021

Tarsus Pharmaceuticals, Inc. Presents Data from Two Pioneering Studies on the Prevalence and Impact of Demodex Blepharitis at the American Academy of Optometry 2021 Annual Meeting

November 3, 2021

Tarsus to Participate in the Virtual Credit Suisse 30th Annual Healthcare Conference

November 1, 2021

Tarsus Pharmaceuticals, Inc. Appoints Pharmaceutical and Healthcare Industry Leader Rosemary A. Crane to Board of Directors

August 11, 2021

Tarsus Pharmaceuticals, Inc. Reports Second Quarter 2021 Financial Results and Provides Business and Clinical Updates

August 3, 2021

Tarsus Pharmaceuticals, Inc. Presents New Saturn-1 Pivotal Trial Data and Titan Real-World Prevalence Study Results at ASCRS 2021

July 23, 2021

Tarsus Pharmaceuticals, Inc. to Participate in the Ladenburg Thalmann 2021 Virtual Healthcare Conference

July 6, 2021

Tarsus Pharmaceuticals, Inc. to Participate in the Raymond James 2021 Human Health Innovation Conference

June 21, 2021

Tarsus Pharmaceuticals, Inc. Announces Positive Results of Saturn-1 Pivotal Trial Evaluating TP-03 for the Treatment of Demodex Blepharitis

June 20, 2021

Tarsus Pharmaceuticals, Inc. Schedules Conference Call and Webcast to Announce Saturn-1 Phase 2b/3 Pivotal Trial Results for TP-03 for the Treatment of Demodex Blepharitis

June 17, 2021

Tarsus Pharmaceuticals, Inc. Initiates Phase 1 Callisto Trial of TP-05, a Novel, Oral, Non-Vaccine Therapeutic for the Prevention of Lyme Disease

June 15, 2021

Tarsus Pharmaceuticals, Inc. to Present at the Jefferies Virtual Healthcare Conference

May 23, 2021

Tarsus Pharmaceuticals, Inc. Reports First Quarter 2021 Financial Results and Provides Business and Clinical Updates

May 10, 2021

Tarsus Pharmaceuticals, Inc. Initiates Saturn-2, Second Pivotal Phase 3 Trial Evaluating the Safety and Efficacy of TP-03 for the Treatment of Demodex Blepharitis

May 5, 2021

Tarsus Pharmaceuticals, Inc. Announces FDA Acceptance of Investigational New Drug Application for TP-05 for Lyme Disease Prevention

May 3, 2021

Tarsus Pharmaceuticals, Inc. Presents Results of Pioneering Atlas Study at ARVO 2021 Annual Meeting Demonstrating the Functional and Psychosocial Impact of Demodex Blepharitis

May 2, 2021

Tarsus Pharmaceuticals, Inc. to Present at the BofA Securities 2021 Virtual Health Care Conference

April 26, 2021

Tarsus Pharmaceuticals, Inc. Reports Full-Year 2020 Financial Results and Business and Clinical Updates

March 30, 2021

Tarsus Pharmaceuticals and LianBio Announce Strategic Partnership to Develop and Commercialize TP-03 in Greater China for the Treatment of Demodex Blepharitis and Meibomian Gland Disease

March 28, 2021

Tarsus Pharmaceuticals, Inc. Appoints Bryan Wahl, MD, JD as General Counsel

January 18, 2021

Tarsus Pharmaceuticals, Inc. Appoints Dianne Whitfield as Chief Human Resources Officer

January 6, 2021

Tarsus Pharmaceuticals, Inc. to Present at the 2021 ICR Virtual Conference

January 4, 2021

Decks in 2021